Novo Nordisk to Acquire Emisphere Technologies for $1.8B

Shots:

  • Novo Nordisk to acquire all outstanding shares of Emisphere for $1.35B and also acquires royalty stream obligations to the firm’s biggest shareholder (MHR) for $450M, making a total deal value as $1.8B
  • Novo Nordisk eliminates its future royalty obligations to Emisphere and MHR & obtains full access to the Eligen SNAC technology platform, thus enabling Novo Nordisk to expand its portfolio of oral biologics across therapy areas
  • The acquisition will provide Novo Nordisk full rights of the Eligen’s SNAC technology, which has been used under a 2007 license agreement to develop the first oral biologic, Rybelsus for T2D

Click here ­to­ read full press release/ article | Ref: Novo Nordisk | Image: SRX

The post Novo Nordisk to Acquire Emisphere Technologies for .8B first appeared on PharmaShots.

Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B

Shots:

  • Dyno to receive upfront and is eligible to receive ~$1.8B milestones including development and commercial milestones along with royalties on any product emerges during the collaboration
  • Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy while Roche and Spark will conduct preclinical, clinical, and commercialization activities for the products using the novel capsids
  • The collaboration leverages Dyno’s CapsidMap platform for the development of next-generation AAV vectors for CNS diseases and liver-directed therapies for the portfolio of both Roche and Spark

    Click here to­ read the full press release/ article | Ref: Dyno Therapeutics | Image: Oncology Nurse Advisor

The post Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~.8B first appeared on PharmaShots.